HMG-CoA Reductase (HMGCR)

HMG-CoA Reductase (HMGCR) is the rate-limiting enzyme for cholesterol synthesis in the conversion of HMG-CoA to mevalonate. HMGCR is found in eukaryotes and prokaryotes. The phylogenetic analysis has revealed two classes of HMG-CoA reductase, the Class I enzymes of eukaryotes and some archaea and the Class II enzymes of eubacteria and certain other archaea.

Both in eukaryotes and in archaebacteria the enzyme HMGCR is known to catalyze an early reaction unique to isoprenoid biosynthesis. In humans, the HMG-CoA reductase reaction is rate-limiting for the biosynthesis of cholesterol and therefore constitutes a prime target of drugs that reduce serum cholesterol levels.

HMG-CoA Reductase (HMGCR) Inhibitors

(3R,5R)-Rosuvastatin

Cat. No.: HY-17504C

(3R,5R)-Rosuvastatin is the (3R,5R)-enantiomer of Rosuvastatin. Rosuvastatin is a competitive **HMG-CoA** reductase inhibitor with an IC_{50} of 11 nM. Rosuvastatin potently blocks **human ether-a-go-go related gene (hERG)** current with an IC_{50} of 195 nM.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

(3R,5S)-Fluvastatin

((3R,5S)-XU 62-320 free acid)

Cat. No.: HY-14664B

(3R,5S)-Fluvastatin is the 3R,5S-isomer Fluvastatin. Fluvastatin (XU 62-320 free acid) is a first fully synthetic, competitive **HMG-CoA reductase** inhibitor with an IC_{50} of 8 nM.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

(3S,5R)-Fluvastatin D6 sodium

((3S,5R)-XU 62-320 D6)

Cat. No.: HY-14664CS

(3S,5R)-Fluvastatin D6 sodium is the deuterium labeled (3S,5R)-Fluvastatin sodium. Fluvastatin is a first fully synthetic, competitive **HMG-CoA reductase** inhibitor with an IC_{50} of 8 nM.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

(3S,5R)-Fluvastatin sodium

((3S,5R)-XU 62-320)

Cat. No.: HY-14664C

(3S,5R)-Fluvastatin sodium ((3S,5R)-XU 62-320) is the (3S,5R)-enantiomer of Fluvastatin. Fluvastatin is a first fully synthetic, competitive **HMG-CoA reductase** inhibitor with an IC_{50} of 8 nM.



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg

(3S,5R)-Fluvastatin-d7 sodium

((3S,5R)-XU 62-320-d7 sodium)

Cat. No.: HY-14664CS1

(3S,5R)-Fluvastatin-d7 sodium ((3S,5R)-XU 62-320-d7 sodium) is the deuterium labeled (3S,5R)-Fluvastatin sodium. (3S,5R)-Fluvastatin sodium ((3S,5R)-XU 62-320) is the (3S,5R)-enantiomer of Fluvastatin.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

(3S,5R)-Rosuvastatin

Cat. No.: HY-17504D

(3S,5R)-Rosuvastatin is the (3S,5R)-enantiomer of Rosuvastatin. Rosuvastatin is a competitive **HMG-CoA** reductase inhibitor with an IC_{50} of 11 nM. Rosuvastatin potently blocks **human ether-a-go-go related gene (hERG)** current with an IC_{50} of 195 nM.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

(Rac)-5-Keto Fluvastatin

(3-Hydroxy-5-Keto Fluvastatin)

Cat. No.: HY-135358

(Rac)-5-Keto Fluvastatin (3-Hydroxy-5-Keto Fluvastatin) is an impurity of Fluvastatin (XU 62320). Fluvastatin is a HMG-CoA reductase inhibitor with an IC_{50} of 8 nM.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg

(rel)-Atorvastatin

Cat. No.: HY-B0589A

(rel)-Atorvastatin, a relative configuration of Atorvastatin. Atorvastatin is an orally active **HMG-CoA** reductase inhibitor, has the ability to effectively decrease blood lipids. Atorvastatin inhibits human SV-SMC proliferation and invasion with IC_{50}s of 0.39 μM and 2.39 μM, respectively.



Relative stereochemistry

Purity: >98%
Clinical Data: Launched
Size: 10 mg, 50 mg, 100 mg

2'-Ethyl Simvastatin

Cat. No.: HY-135402

2'-Ethyl Simvastatin (compound 6) is a Mevinolin analog, with **HMG-CoA reductase** inhibition.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

3α-Hydroxy pravastatin sodium

Cat. No.: HY-136347

3α-Hydroxy pravastatin sodium is the major metabolite of Pravastatin. Pravastatin is a competitive HMG-CoA reductase inhibitor.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Tel: 609-228-6898 Fax: 609-228-5909 Email: sales@MedChemExpress.com

Atorvastatin

Cat. No.: HY-B0589

Atorvastatin is an orally active **HMG-CoA** reductase inhibitor, has the ability to effectively decrease blood lipids. Atorvastatin inhibits human SV-SMC proliferation and invasion with **IC_{50}**s of 0.39 μM and 2.39 μM, respectively.



Purity: 99.05%
Clinical Data: Launched
Size: 10 mM × 1 mL, 10 mg, 50 mg, 100 mg

Atorvastatin hemicalcium salt

(CI-981; Atorvastatin hemicalcium)

Cat. No.: HY-17379

Atorvastatin hemicalcium salt (CI-981) is an orally active **3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA)** reductase inhibitor, has the ability to effectively decrease blood lipids.



Purity: 99.94%
Clinical Data: Launched
Size: 10 mM × 1 mL, 10 mg, 50 mg, 100 mg, 200 mg, 500 mg

Atorvastatin lactone

Cat. No.: HY-101873

Atorvastatin lactone is a prodrug form of atorvastatin. Atorvastatin is an orally active **3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA)** reductase inhibitor.



Purity: 96.95%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg

Atorvastatin lactone D5

Cat. No.: HY-101873S

Atorvastatin lactone D5 is a deuterated form of Atorvastatin lactone (HY-101873). Atorvastatin lactone is a prodrug form of atorvastatin. Atorvastatin is an orally active **3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA)** reductase inhibitor.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Atorvastatin-d5 hemicalcium

Cat. No.: HY-B0589S

Atorvastatin-d5 hemicalcium is the deuterium labeled Atorvastatin. Atorvastatin hemicalcium is an orally active **HMG-CoA** reductase inhibitor, has the ability to effectively decrease blood lipids.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Atorvastatin-d5 sodium

Cat. No.: HY-B0589S1



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 10 mg

Cerivastatin

Cat. No.: HY-129458

Cerivastatin is a synthetic lipid-lowering agent and a highly potent, well-tolerated and orally active **HMG-CoA reductase** inhibitor, with a **Ki** of 1.3 nM/L. Cerivastatin reduces low-density lipoprotein cholesterol levels.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Cerivastatin sodium

Cat. No.: HY-109523

Cerivastatin sodium is a synthetic lipid-lowering agent and a highly potent, well-tolerated and orally active **HMG-CoA reductase** inhibitor, with a **Ki** of 1.3 nM/L. Cerivastatin sodium reduces low-density lipoprotein cholesterol levels.



Purity: 99.89%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg

Clinofibrate

(S-8527)

Cat. No.: HY-13528

Clinofibrate (S-8527) is a hypelipidemic agent and a **HMG-CoA** reductase inhibitor.



Purity: 99.70%
Clinical Data: Launched
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg, 200 mg

Epi Lovastatin-d3

Cat. No.: HY-N0504S

Epi Lovastatin-d3 is the deuterium labeled Lovastatin. Lovastatin is a cell-permeable **HMG-CoA reductase** inhibitor used to lower cholesterol.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 10 mg

Fluvastatin

(XU 62-320 free acid)

Cat. No.: HY-14664

Fluvastatin (XU 62-320 free acid) is a first fully synthetic, competitive **HMG-CoA reductase** inhibitor with an IC_{50} of 8 nM. Fluvastatin protects vascular smooth muscle cells against oxidative stress through the Nrf2-dependent antioxidant pathway.



Purity: >98%
Clinical Data: Launched
Size: 1 mg, 5 mg

Fluvastatin D6 sodium

(XU 62-320 (D6))

Cat. No.: HY-14664AS

Fluvastatin D6 sodium (XU 62-320 D6) is deuterium labeled Fluvastatin sodium. Fluvastatin sodium (XU 62320) is a first fully synthetic, competitive **HMG-CoA reductase** inhibitor with an IC_{50} of 8 nM.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Fluvastatin sodium

(XU 62-320)

Cat. No.: HY-14664A

Fluvastatin sodium (XU 62320) is a first fully synthetic, competitive **HMG-CoA reductase** inhibitor with an IC_{50} of 8 nM. Fluvastatin sodium protects vascular smooth muscle cells against oxidative stress through the Nrf2-dependent antioxidant pathway.



Purity: 99.90%
Clinical Data: Launched
Size: 10 mM × 1 mL, 50 mg, 100 mg

Hesperetin 7-O-glucoside

Cat. No.: HY-125130

Hesperetin 7-O-glucoside is produced by the enzymatic conversion of Hesperidin. Hesperetin 7-O-glucoside is a potent **human HMG-CoA reductase** inhibitor and also effectively inhibits the growth of **Helicobacter pylori**. Antihypertensive effect.



Purity: 98.08%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

HMG499

Cat. No.: HY-114316

HMG499 is a potent and selective **HMG-CoA reductase** inhibitor with an **IC_{50}** of 0.41 μM. HMG499 can prevent statins-induced accumulation of HMGCR, reduce serum cholesterol levels and decrease atherosclerosis.



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg

Lovastatin

(Mevinolin)

Cat. No.: HY-N0504

Lovastatin is a cell-permeable **HMG-CoA reductase** inhibitor used to lower cholesterol.



Purity: 99.93%
Clinical Data: Launched
Size: 10 mM × 1 mL, 10 mg, 50 mg, 100 mg

Lovastatin hydroxy acid sodium

(Mevinolinic acid sodium)

Cat. No.: HY-123672

Lovastatin hydroxy acid sodium (Mevinolinic acid sodium) is a highly potent inhibitor of HMG-CoA reductase with a K_i of 0.6 nM.



Purity: 98.62%
Clinical Data: No Development Reported
Size: 5 mg

Lovastatin-d3

(Mevinolin-d3)

Cat. No.: HY-N0504S2

Lovastatin-d3 is deuterium labeled Lovastatin. Lovastatin is a cell-permeable HMG-CoA reductase inhibitor used to lower cholesterol.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Lovastatin-d3 hydroxy acid sodium

Cat. No.: HY-123672S

Lovastatin-d3 hydroxy acid (Mevinolinic acid-d3) sodium is the deuterium labeled Lovastatin hydroxy acid sodium. Lovastatin hydroxy acid sodium (Mevinolinic acid sodium) is a highly potent inhibitor of HMG-CoA reductase with a K_i of 0.6 nM.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 10 mg

Lovastatin-d9

Cat. No.: HY-N0504S1

Lovastatin-d9 is the deuterium labeled Lovastatin. Lovastatin is a cell-permeable **HMG-CoA reductase** inhibitor used to lower cholesterol.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Meglutol

(Dicrotalic acid; 3-Hydroxy-3-methylglutaric acid) Cat. No.: HY-B1189

Meglutol is an antilipemic agent which lowers cholesterol, triglycerides, serum beta-lipoproteins and phospholipids, and inhibits the activity of hydroxymethylglutarryl CoA reductases, which is the rate limiting enzyme in the biosynthesis of cholesterol.



Purity: ≥98.0%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 10 mg

Mevastatin

(Compactin; ML236B) Cat. No.: HY-17408

Mevastatin (Compactin) is a first **HMG-CoA reductase** inhibitor that belongs to the statins class. Mevastatin is a lipid-lowering agent, and induces **apoptosis**, arrests cancer cells in G_0/G_1 phase.



Purity: 99.20%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 50 mg, 100 mg, 500 mg

Monacolin J

(Antibiotic MB 530A; Lovastatin diol lactone) Cat. No.: HY-104051

Monacolin J is an inhibitor of cholesterol biosynthesis, and inhibits the activity of **HMG-CoA reductase**.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Pitavastatin

(NK-104) Cat. No.: HY-B0144A

Pitavastatin (NK-104) is a potent **hydroxymethylglutaryl-CoA (HMG-CoA) reductase** inhibitor. Pitavastatin inhibits cholesterol synthesis from acetic acid with an IC_{50} of 5.8 nM in HepG2 cells.



Purity: >98%
Clinical Data: Launched
Size: 1 mg, 5 mg

Pitavastatin Calcium

(NK-104 hemicalcium; Pitavastatin hemicalcium) Cat. No.: HY-B0144

Pitavastatin Calcium (NK-104 hemicalcium) is a potent **hydroxymethylglutaryl-CoA (HMG-CoA) reductase** inhibitor. Pitavastatin Calcium (NK-104 hemicalcium) inhibits cholesterol synthesis from acetic acid with an IC_{50} of 5.8 nM in HepG2 cells.



Purity: 99.45%
Clinical Data: Launched
Size: 10 mM × 1 mL, 10 mg, 50 mg, 100 mg

Pitavastatin D4

(NK-104 D4) Cat. No.: HY-B0144AS

Pitavastatin D4 (NK-104 D4) is deuterium labeled Pitavastatin. Pitavastatin is a potent HMG-CoA reductase inhibitor.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Pitavastatin-d4 hemicalcium

(NK-104-d4 hemicalcium; Pitavastatin-d4 hemicalcium) Cat. No.: HY-B0144S

Pitavastatin-d4 (hemicalcium) is deuterium labeled Pitavastatin (Calcium). Pitavastatin Calcium (NK-104 hemicalcium) is a potent hydroxymethylglutaryl-CoA (HMG-CoA) reductase inhibitor.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Pravastatin

(CS-514) Cat. No.: HY-B0165

Pravastatin (CS-514) is a competitive **HMG-CoA reductase** inhibitor against sterol synthesis with IC_{50} of 5.6 μM.



Purity: >98%
Clinical Data: Launched
Size: 5 mg, 10 mg

Pravastatin sodium

(CS-514 sodium) Cat. No.: HY-B0165A

Pravastatin sodium (CS-514 sodium) is an HMG-CoA reductase inhibitor against sterol synthesis with IC_{50} of 5.6 μM.



Purity: 99.49%
Clinical Data: Launched
Size: 10 mM × 1 mL, 10 mg, 50 mg, 100 mg, 200 mg

Pravastatin-13C,d3 sodium

(CS-514-13C,d3 sodium) Cat. No.: HY-B0165AS

Pravastatin-13C,d3 (sodium) is the 13C- and deuterium labeled. Pravastatin sodium (CS-514 sodium) is an HMG-CoA reductase inhibitor against sterol synthesis with IC50 of 5.6 μM.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Pravastatin-d3 sodium salt

Cat. No.: HY-B0165CS

Pravastatin-d3 (CS-514-d3) sodium salt is the deuterium labeled Pravastatin sodium salt. Pravastatin (CS-514) sodium salt is a competitive **HMG-CoA reductase** inhibitor against sterol synthesis with IC_{50} of 5.6 μM.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Rosuvastatin

(ZD 4522)

Cat. No.: HY-17504A

Rosuvastatin (ZD 4522) is a competitive **HMG-CoA** reductase inhibitor with an **IC_{50}** of 11 nM.



Purity: >98%
Clinical Data: Launched
Size: 1 mg, 5 mg

Rosuvastatin Calcium

(Rosuvastatin hemicalcium; ZD 4522 Calcium)

Cat. No.: HY-17504

Rosuvastatin Calcium (Rosuvastatin hemicalcium) is a competitive **HMG-CoA** reductase inhibitor with an **IC_{50}** of 11 nM.



Purity: 99.94%
Clinical Data: Launched
Size: 10 mM × 1 mL, 10 mg, 50 mg, 100 mg, 200 mg

Rosuvastatin D3

(ZD 4522 D3)

Cat. No.: HY-17504AS

Rosuvastatin D3 (ZD 4522 D3) is a deuterium labeled Rosuvastatin. Rosuvastatin (ZD 4522) is a competitive HMG-CoA reductase inhibitor with an IC_{50} of 11 nM.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg

Rosuvastatin D3 Sodium

Cat. No.: HY-17504BS

Rosuvastatin D3 Sodium is deuterium labeled Rosuvastatin, which is a competitive inhibitor of HMG-CoA reductase with IC50 of 11 nM.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Rosuvastatin D6 Sodium

Cat. No.: HY-17504BS1

Rosuvastatin D6 Sodium is deuterium labeled Rosuvastatin, which is a competitive inhibitor of HMG-CoA reductase with IC50 of 11 nM.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Rosuvastatin-d6 calcium

Cat. No.: HY-17504S

Rosuvastatin D6 Calcium is deuterium labeled Rosuvastatin, which is a competitive inhibitor of HMG-CoA reductase with IC50 of 11 nM.



Purity: 98.54%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

S-2E

Cat. No.: HY-139134

S-2E is an orally active and noncompetitive **HMG-CoA reductase** and **acetyl-CoA carboxylase** inhibitor. S-2E has an anti-hyperlipidemic action. S-2E has the potential for familial hypercholesterolemia and mixed hyperlipidemia research.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Simvastatin

(MK 733)

Cat. No.: HY-17502

Simvastatin (MK 733) is a competitive inhibitor of **HMG-CoA reductase** with a K_i of 0.2 nM.



Purity: 99.45%
Clinical Data: Launched
Size: 50 mg, 100 mg, 200 mg, 500 mg

Simvastatin hydroxy acid sodium

(Tenivastatin sodium; Simvastatin Impurity A sodium)

Cat. No.: HY-115292

Simvastatin hydroxy acid sodium (Tenivastatin sodium; Simvastatin Impurity A sodium) is an active hydrolytic metabolite of Simvastatin (HY-17502). Simvastatin shows a inhibition of **HMG-CoA reductase** with a K_i value of 0.12 nM.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Simvastatin-d6

(MK 733-d6)

Cat. No.: HY-110231

Simvastatin-d6 (MK 733-d6) is the deuterium labeled Simvastatin. Simvastatin (MK 733) is a competitive inhibitor of **HMG-CoA reductase** with a K_i of 0.2 nM.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

SR12813

(GW 485801)

Cat. No.: HY-100793

SR12813 (GW 485801) is an inhibitor of **3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase**, with an IC_{50} value of 0.85 μM. SR12813 is also an efficient agonist of human pregnane X receptor (**hPXR**). SR12813 can strongly bind to hPXR but not to mouse PXR (mPXR).



Purity: 99.39%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg, 200 mg

β-Amyrin palmitate

Cat. No.: HY-N2924

β-Amyrin palmitate shows HMG-CoA reductase inhibition. And β-Amyrin palmitate has anti-diabetes mellitus activity.



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg